ANTISENSE TARGETING DYNAMIN 2 AND USE FOR THE TREATMENT OF CENTRONUCLEAR MYOPATHIES AND NEUROPATHIES

摘要

The present invention concerns the use of antisense oligonucleotides (AON) capable of inhibiting expression of dynamin 2, advantageously human dynamin 2, for use in the treatment of Charcot-Marie-Tooth disease (CMT) and centronuclear myopathies (CNM).